December 3, 2020
Upcoming Potential Value Generating Milestones. Read the Press Release
December 1st, 2020
Biophytis is participating to: – The Geneva European Midcap digital event, December 1rst & 2 2020 – The “Anticovid” Biotech sector conference organized by the SFAF on Wednesday, December 9 – The 13th International SCWD virtual conference, December 11-13 2020
NOVEMBER 20, 2020
Paris Court of Appeal rules in Biophytis’ favor in connection with the dispute with NEGMA. Read the Press Release
NOVEMBER 6, 2020
Interview of Stanislas Veillet, CEO of Biophytis on Les Pros de l’Eco (in French)
OCTOBER 26, 2020
Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
October 16, 2020
Biophitys will participate in the following events: Mid-Cap Event :October 19 & 20th Galien Week of Innovation: Oct 26-30
October 13, 2020
First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
September 30, 2020
Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release
September 30, 2020
Biophytis announces a € 10 million capital increase through private placement. Read the Press Release
September 30, 2020
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release